JCAR 023

Drug Profile

JCAR 023

Alternative Names: Anti-CD171-CAR-T-cell-therapy-Juno-Therapeutics; Anti-CD171-chimeric-antigen-receptor-T-cell-therapy-Juno-Therapeutics; Anti-CD171-human-scFv-CAR-T-cell-product-Juno-Therapeutics; Anti-CD171-human-scFv-CAR-T-cell-therapy-Juno-Therapeutics; Anti-CD171-human-single-chain-variable-fragment-CAR-T-cell-therapy-Juno Therapeutics; Anti-L1CAM-CAR-T-cell-therapy-Juno-Therapeutics; Anti-neural-cell-adhesion-molecule-L1-chimeric-antigen-receptor-T-cell-therapy-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-scFv-CAR-T-cell-product-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-scFv-CAR-T-cell-therapy-Juno Therapeutics; Anti-neural-cell-adhesion-molecule-L1-human-single-chain-variable-fragment-CAR-T-cell-therapy-Juno Therapeutics; JCAR023

Latest Information Update: 28 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Childrens Research Institute
  • Developer Juno Therapeutics
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Neuroblastoma

Most Recent Events

  • 28 Apr 2018 No recent reports of development identified for phase-I development in Neuroblastoma(In adolescents, In children, In infants, Recurrent, Refractory metastatic disease) in USA (Parenteral)
  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 19 Mar 2015 Phase-I clinical trials in Neuroblastoma (In infants, In children, In adolescents, Recurrent, Refractory metastatic disease) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top